In 2026, Provigil (modafinil) continues to be the primary clinical standard for restoring cognitive alertness. Unlike traditional stimulants, it is a eugeroic—a wakefulness-promoting agent designed to keep the brain in a state of natural-feeling arousal without the intense "jitters" or crash associated with amphetamines.